MediWound

Michael Okunewitch maintains a Buy rating on Mediwound (MDWD) with a $30 target, citing EscharEx's potential in chronic wound care. EscharEx, supported by Phase 3 studies, aims to capture a significant market share, projecting a $2.5 billion opportunity in diabetic foot and venous leg ulcers. Citi also maintains a Buy rating with a $25 target.

MediWound to host virtual KOL event on Jan 8, 2025, focusing on EscharEx, a biologic drug for chronic wound debridement, including Phase III VALUE study in venous leg ulcers and its commercial potential.

MediWound to host virtual KOL event on Jan 8, 2025, discussing EscharEx Phase III VALUE study in venous leg ulcers (VLUs) and its commercial potential. Event features clinical experts discussing Phase II results, Phase III VALUE study, unmet needs in VLU and diabetic foot ulcers (DFUs) treatment, and EscharEx's competitive advantages.

MediWound Ltd. will host a virtual KOL event on Jan 8, 2025, discussing EscharEx®, a biologic drug in late-stage development for chronic wound debridement, including the Phase III VALUE study in venous leg ulcers and its commercial potential. The event features clinical experts John C. Lantis II, Vickie R. Driver, and Robert J. Snyder, discussing EscharEx's Phase II results, upcoming Phase III study, unmet needs in wound care, and competitive advantages.

MediWound reports Q3 revenue of $4.355M, below consensus of $6.01M. CEO Ofer Gonen highlights NexoBrid’s pediatric approval in the U.S. and the upcoming Phase 3 trial for EscharEx in venous leg ulcers. A Phase 2 study vs. collagenase is planned for 2025, and Phase 2/3 preparations for diabetic foot ulcers are underway. Manufacturing expansion is on track to meet global demand for NexoBrid.

MediWound announces financial results for Q3 2024, including FDA approval of NexoBrid for pediatric use, $25M financing, and €16.25M EIC funding. NexoBrid demand exceeds capacity, with new manufacturing facility commissioning underway. EscharEx Phase 3 study for venous leg ulcers to commence post-IND submission by year-end, with a planned head-to-head Phase 2 study vs. collagenase in 2025. MediWound anticipates $20M revenue for 2024, down from prior guidance of $24M due to reduced BARDA funding.

MediWound reports FDA approval for pediatric use of NexoBrid, progress in Phase 3 trial for EscharEx, $4.4 million quarterly revenue, increased net loss, and secured $25 million PIPE investment and €16.25 million from EIC.

MediWound to initiate a controlled, multicenter Phase II clinical study evaluating EscharEx® against collagenase ointment for treating venous leg ulcers (VLUs) in 2025, supporting its Biologics License Application (BLA) and commercialization strategy. The study will involve 45 patients across multiple sites in the U.S. and Europe, with key safety and efficacy endpoints assessed. MediWound has secured R&D collaborations with Solventum and Mölnlycke to enhance trial consistency and patient outcomes.

MediWound announces Phase II study comparing EscharEx® to collagenase for treating venous leg ulcers, aiming to support BLA and strengthen commercialization strategy.